On December 1, 2023, Biological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced it has received IRB approval and will soon begin to enroll patients in its ExoLuminate™ clinical study to validate its pancreatic ductal adenocarcinoma (PDAC) lab-developed test (LDT). "Using novel data, we are one of the first companies in this country to use exosome-isolation for early detection of pancreatic disease. We are accelerating its application by initiating the ExoLuminate registry trial, which will enroll for high-risk or clinically suspicious patients and their family members that share risk factors," said Harmeet Dhani, MD, MSc, Director of Medical Affairs at Biological Dynamics.
Biological Dynamics Receives IRB Approval for Its Exosome Detection ExoVerita Platform for Early Disease Diagnostics; First Target Will Be Pancreatic Cancer
Login Or Register To Read Full Story